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Abstract
There is growing evidence that the complex clinical manifestations of lysosomal storage diseases (LSDs) are not fully
explained by the engorgement of the endosomal-autophagic-lysosomal system. In this review, we explore current knowledge
of common pathogenetic mechanisms responsible for the early onset of tissue abnormalities of two LSDs,
Mucopolysaccharidosis type II (MPSII) and Niemann-Pick type C (NPC) diseases. In particular, perturbations of the homeosta-
sis of glycosaminoglycans (GAGs) and cholesterol (Chol) in MPSII and NPC diseases, respectively, affect key biological pro-
cesses, including morphogen signaling. Both GAGs and Chol finely regulate the release, reception and tissue distribution of
Shh. Hence, not surprisingly, developmental processes depending on correct Shh signaling have been found altered in both
diseases. Besides abnormal signaling, exaggerated activation of microglia and impairment of autophagy and mitophagy occur
in both diseases, largely before the appearance of typical pathological signs.
Introduction
For many years the engorgement of lysosomes with undigested
macromolecules and the subsequent functional cell impair-
ment have been accepted as primary causes for the pathogene-
sis of many lysosomal storage diseases (LSDs). However, the
lysosomal-dependent cellular engulfment of undigested mate-
rial has never fully explained the variety of phenotypes dis-
played by different LSDs. In recent decades, a more nuanced
approach has disclosed the important roles of altered autoph-
agy and stimulation of inflammatory responses in the pathol-
ogy of LSDs.
The interplay between the accumulation/mislocalization of
substrates and alteration of signaling pathways is also gaining
attention in the context of LSDs (1). Glycosaminoglycan (GAG)
fragments accumulating in Mucopolysaccharidoses are typi-
cally attached to proteoglycans, which acting as co-receptors,
finely regulate the activity of major signaling pathways (2).
Gangliosides, sphingolipids and cholesterol (Chol) accumulating
in Lipidoses assemble cell surface microdomains, including cav-
eolae (3), lipid rafts (4) and glycosphingolipids-enriched microdo-
mains (5), which serve as platforms for signal transduction.
Therefore, aberrant signaling cascades contribute to the pheno-
types of LSDs affected patients with alterations in autophagy
and mitophagy, leading to neuroinflammation and progressive
lysosomal substrate storage.
Among signaling pathways modulated by GAGs, glyco-
conjugated lipids and Chol, Sonic hedgehog (Shh) and Wnt/b-
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catenin play a key role in morphogenetic processes (6) and adult
tissue homeostasis (7). Both Shh and Wnt morphogens are co-
valently linked to lipids and associate with lipoprotein particles,
which are used as vehicles to ensure their movement within
the extracellular space. Extracellular matrix GAGs with distinct
modification patterns generate a specific code that shapes the
gradient-based activity of both Shh and Wnt signals (8). The cur-
rent view posits that Shh monomers associate with lipoprotein
particles via palmitoyl and Chol moieties forming multimeric
complexes that further interact with GAG chains (8), by means
of positively charged aminoacid residues of the Cardin-
Weintraub (CW) motif (9). This interaction is particularly rele-
vant for proper Shh gradient formation during tissue morpho-
genesis (8). Hence, perturbations of GAG catabolism or
intracellular movement of endocytosed Chol may thereby alter
Shh signaling. Progressively uncleared GAGs may interfere ex-
tracellularly with Shh ligand, preventing its binding to Patched
(Ptch), and therefore blocking Shh pathway transduction at the
primary cilium. On the other hand, when Chol is trapped in
endo/lysosomes it may not bind and activate both Shh and
Smoothened (Smo). Also, lysosomal Chol, as well as GAG en-
gorgement, may perturb the autophagic flux, leading to cell
damage (Fig. 1).
The enrichment of Chol in lipid rafts, as a means to set the
necessary microenvironment for signal transduction, is being
re-framed in light of the discovery of a high-affinity Chol-bind-
ing motif in the intracellular juxtamembrane domain of recep-
tor proteins (10). The precise arrangement of this motif, which
is called ‘cholesterol recognition aminoacid consensus (CRAC)’
and its mirror motif, CARC, in the inner and outer leaflet of the
plasma membrane, respectively, suggests a direct role of Chol
in the activation processes.
We here overview current findings supporting a novel con-
cept, whereby alterations of different key biological processes,
including morphogenetic pathways (see Table 1), autophagic
flux and mitophagy, may account for the onset of early LSD-
related tissue manifestations. To this purpose, we examine two
distinct LSD diseases: Mucopolysaccharidosis type II (MPSII;
Hunter syndrome/disease) and Niemann-Pick C 1 and 2 (NPC1,
2), which despite affecting the GAG catabolism and intracellular
Figure 1. Model for the hypothetical role of lysosomal engorgement in the onset of Sonic Hedgehog (Shh) pathway alterations. When cholesterol (Chol) progressively
accumulates inside lysosomes it may not bind and activate Smoothened (Smo). For simplicity, we omitted the potential prevention of Hedgehog ligand cholesteryla-
tion, due to lysosomal storage. On the other hand, lysosomal Chol, as well as GAGs engorgement, may perturb the autophagic flux, leading to cell damage.
Progressively uncleared GAGs may also interfere extracellularly with Shh ligand, preventing its binding to Patched (Ptch), and therefore blocking Shh pathway trans-
duction (see text for more details).
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trafficking of endocytosed Chol, respectively, appear to share
common related pathogenic mechanisms.
Mucopolysaccharidosis type II (Hunter syndrome)
MPSII was originally described by its physical feature of ‘gar-
goylism’ (16). Since the discovery of GAGs in the urine of af-
fected patients, the result of lysis of cells sloughed from the
kidney, ureters and bladder (17), and the identification of the de-
fective enzyme, diagnosis became more precise, enabling the
discrimination between the autosomal recessive Hurler’s dis-
ease (MPS I) due to the lack of alpha-L-iduronidase and the sex-
linked Hunter disease, characterized by the lack of iduronate-2-
sulfatase (IDS). The latter shares delayed motor development,
hepatosplenomegaly, heart disease and short stature with the
former, but MPSII patients also display a high frequency of diar-
rhea (18). In addition, MPSII patients exhibit joint problems with
contractures, pseudopapilloedema or papilloedema without vi-
sual loss, myocardial enlargement and pulmonary dysfunction
(19). The early separation of the disorder into severe and mild
forms (18) was later explained by the occurrence of residual en-
zymatic activity and by different types of mutations (20).
Nonetheless, 14% of affected patients are not classifiable (18)
and there are families in which, due to environmental variables
or modifying genes, both severe and mild cases occur (21,22).
Enzyme replacement therapy (ERT) first attempted with fresh
frozen plasma (23) represents the current gold standard thera-
peutic approach, despite being unable to treat the neurological
symptoms due to the failure of the recombinant enzyme to
cross the blood brain barrier (BBB) (24).
While also prominent in MPSI (25), heart problems are very
common in MPSII, ranging from 75% of mildly affected cases
(18) to 91% of all cases (26). Mitral and aortic valve disease are
the most frequent findings, but myocardial thickening, conduc-
tion disturbances, including arrhythmias, coronary arterial nar-
rowing and myocardial infarction have been described (27). And
sudden death can also occur.
Impaired cell signaling and cardiac defects in Hunter
syndrome
The first example of ultrastructural defects of the ECM related
to developmental cardio-vascular abnormalities is provided by
the great similarity of Loeys-Dietz syndrome with Marfan syn-
drome (28). While the connective tissue fibrillin 1, defective in
Marfan syndrome, was initially thought to cause the cardiac
pathology by decreasing the structural strength of the connec-
tive tissue, it now seems that alterations of the TGFb signaling
are more clearly responsible for the disease, in agreement with
the pathogenic role of TGFb mutations in Loeys-Dietz syndrome
(29).
Similarly, GAGs that are structurally abnormal in MPSs alter
different intracellular signaling pathways, including Shh (30). In
particular, impaired Shh signaling whose activity is tightly re-
lated to sulfated iduronic acid (2) has been recently shown asso-
ciated with impaired heart development (13). Indeed, IDS
knockout mice exhibit impaired Shh signaling and ECG abnor-
malities, particularly a prolonged PR interval, before the onset
of a large buildup of GAGs in lysosomes (13).
A close link between impaired extracellular matrix GAGs
composition and heart development is also illustrated by a new
storage disease found in Yakuts, a Siberian population.
Mutations in VPS33A, a protein involved in endocytic and auto-
phagic pathways, result in increased heparan sulfate levels (31).
This severe disorder shows classic signs of MPSs and most
patients exhibit congenital heart disease, with coarse facial fea-
tures, barrel-shaped chest, and mental retardation with delayed
myelination. Early obstructive lung disease occurs as well, and
most patients die before 2 years of age due to cardiorespiratory
disease. Although it has not been yet demonstrated in any ver-
tebrate animal model for the disease, the severe heart disease
leading to early death is likely to be due to heparan sulfate-
mediated changes in cell signaling.
Perhaps, similar alterations of cell signaling caused by
matrix-induced alterations of cell signaling contribute to other
organ pathologies in Hunter syndrome. For instance, the severe
diarrhea may not just be secondary to compression of the gut
by splenomegaly. Shh and Indian hedgehog are essential for
smooth muscle formation, while Shh is essential for gut inner-
vation (32). Mesenchymal Wnt signaling in the developing gut
seems to decrease as extracellular matrix formation increases
(33). While only increased membranous cytoplasmic bodies
have been observed in an ultrastructural study of the rectal wall
in MPS II (34), decreases or alterations in the enteric nervous
system or smooth muscle might be responsible for the diarrhea
so frequently seen.
The role of autophagy in Hunter syndrome CNS and
heart-related manifestations
There are several interesting studies implicating alterations of
autophagy in the onset of neurodegeneration of MPS patients
Table 1. LSDs with documented Hedgehog signaling impairment
Lysosomal storage disease Molecular defect Phenotype Reference
Niemann-Pick C1 Shh dysregulation(reduced Ptch
and Smo mRNA and protein
levels)
Shortened primary cilium length
in human patient fibroblasts
Canterini et al. (11)
Niemann-Pick C1 Reduced Ptch1 protein levels Shortened primary cilium length
in human patient fibroblasts
Formichi et al. (12)
Mucopolysaccharidosis Type II Reduced Shh transduction (de-
creased Shh protein and Gli,
Ptch1 mRNA levels)
Reduced cardiac trabeculation in
IDS KO mice and Ids deficient
fish
Costa et al. (13)
Mucopolysaccharidosis Type I Aberrant Indian hedgehog protein
distribution in the growth plate
Structural abnormalities in the
growth plate of MPSI mice
Kingma et al. (14)
Mucopolysaccharidosis Type VII Dysregulated Ihh and Ptch1 mRNA
levels
Impaired endochondral ossifica-
tion in MPSVII dogs vertebrae
Peck et al. (15)
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(35). These studies have mostly been performed in MPSs I, IIIA,
IIIB and VII. In these MPSs, accumulation of GAGs is strikingly
accompanied by accumulation of gangliosides in the brain (36)
as occurs in NPC1, 2 (see below), while increased Chol, which is
implicated in the failure of phagosome-lysosome fusion, is also
detected in neuronal cell membranes of affected patients (37).
Among major consequences of impaired phagosome-lysosome
fusion is mitophagic impairment (digestion of dysfunctional mi-
tochondria), which may lead to apoptosis of affected cells. The
accumulation of damaged mitochondria has been shown in
MPS with subsequent elevation of damaging reactive oxygen
species (ROS) (38). The mitochondrial dysfunction in multiple
LSDs and its consequences for neurodegeneration have been
well reviewed by Saffari et al. (39). Altered mitochondrial func-
tion also seems important in NPC1, 2 (see below). However, it is
the balance of apoptosis [which is not a major process to occur
in NPC1 (see below)] with non-apoptotic death, which is impor-
tant since the latter stimulates the immune system while the
former does not. The pattern recognition receptors (PRR) of the
innate immune system recognize the extracellular GAGs by the
addition of damage associated molecular partners (reviewed in
40), which are known to be involved in microglial activation and
neuroinflammation (41). This microglial activation is responsi-
ble of the proinflammatory/neurodestructive pathway involving
the so called A1 astrocytes (42), which has been found in multi-
ple lysosomal storage disorders (43).
Autophagic processes are very important in early cardiac
morphogenesis, as Atg5-deficient mice and atg5 zebrafish mor-
phants exhibit abnormal heart structures, impaired heart loop-
ing and heart valve development (44). Moreover, defects in
autophagy have been shown in the aging heart and enhancing
autophagic processes delays cardiac aging. Many cardiac pa-
thologies resulting in heart failure (ventricular dilation, cardiac
hypertrophy and fibrosis) involve re-modelling, which is depen-
dent on autophagy (45). The mitophagic pathway seems to have
a homeostatic role in the heart (46). Based on the emphasized
role of autophagy in cardiac health, a number of autophagy-
targeted drugs are being considered in heart diseases. Although
not yet studied in MPSs, altered autophagy may well contribute
to the heart disease as well as to the neurodegeneration in
MPSs.
Thus, while the precise role of mitophagic versus general
autophagic defects remains unclear (see further discussion be-
low for NPC1), the contribution of one or both to MPS pathology
is clear. The role of activated microglia, with their recruitment
of macrophages and other inflammatory cells (47) in neurode-
generation seems paramount. In this light, it is relevant that a
drug targeted at inflammation, pentosan polysulfate, has
shown promising results in the MPS VI rat model (48). The addi-
tion of drugs targeted to inflammatory pathways, especially if
they penetrate the BBB, to enzyme therapy would appear
hopeful.
Niemann-Pick C diseases
Niemann-Pick type C (NPC) disease is an autosomal recessive,
neurodegenerative lysosomal storage disorder with variable
clinical phenotypes (49). The most common presentation of
NPC disease is a child of either sex developing coordination
problems, dysarthria, and hepatosplenomegaly during early
school-age years. Phenotypic manifestations are accompanied
by abnormal intracellular accumulation of Chol and glycosphin-
golipids in a variety of tissues, including the liver and spleen,
and progressive cerebellar degeneration (for a general review,
see 50). The neurological progression of the disorder is relent-
less and characterized by an increasing severity of ataxia, dysar-
thria and dementia until death occurs, usually during the
second decade of life. Seizures are a common manifestation
(49). More severe infantile forms, where liver involvement is se-
vere (50,51), and late-onset forms including Niemann-Pick D
disease (NPD, see below) also occur. The gene underlying 95% of
the cases of this disorder is NPC1, which codes for a multi-pass
transmembrane protein, containing a sterol-sensing domain. It
shows homology to proteins with sterol-binding domains in-
cluding Ptch, HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme
A) reductase, and SCAP (SREBP cleavage-activating protein)
(52,53). Ptch is a transmembrane receptor, which interacts with
Shh, a signaling molecule with covalently attached Chol, while
HMG-CoA reductase and SCAP interact with Chol. Functional
analysis of NPC1 suggests that it is involved in late endosomal
lipid sorting and trafficking (54). While NPC disease is most
commonly associated with mutations in the NPC1 gene (55), it
can also be caused by mutations in a second gene, NPC2, which
encodes a smaller, soluble lysosomal protein, which presents
Chol to NPC1 (56,57). The much greater rarity of NPC2 (5% of
NPC cases) may be due to decreased fertility of male carriers
since NPC2 is a very abundant protein in seminal fluid. NPD is a
milder mutant version of the NPC1 gene that apparently seemed
different, with a large number of cases in an inbred population
in Nova Scotia, until Chol storage was also identified in the dis-
order and mutations in NPC1 were found.
Although there has been some controversy as to whether
Chol storage is causative for the pathology (versus sphingosine
or gangliosides), it now seems clear that ganglioside accumula-
tion is secondary, as in MPSs (58). The success of the Chol se-
questering hydroxypropyl-beta-cyclodextrins (HPbCD) in
treating NPC1 also confirms the primary role of Chol storage.
HPbCD has been previously used to modulate Chol trafficking
across cell membrane (59). Over a decade ago, an efficacious ef-
fect of HPbCD on slowing neurodegeneration in a mouse model
of NPC1 was shown (60). HPbCDs are substituted rings of seven
glucoses and do not cross the BBB. Since it seems counter-
intuitive to treat a CNS disorder with a drug that does not cross
the BBB, and because the effects are small when the drug is only
started at the time of weaning, this drug appeared not particu-
larly promising. Only when therapy was started at postnatal
day 7, with higher doses, results were more dramatic. At this
age the sealing properties of the BBB are not fully mature (61)
and the drug is more slowly eliminated (6 h instead of 3 h; 62).
This Chol-interacting compound is now in Phase I/II trials in
humans, both using intravenous and intrathecal delivery.
Intrathecal delivery has recently been found to significantly de-
lay the pathological progress of NPC1 disease (63,64).
Altered development in Niemann-Pick C diseases
Neurological symptoms, including ataxia, cognitive loss, seiz-
ures and dementia represent the most severe clinical manifes-
tations of the NPC disease. The cerebellum is particularly
affected, with Purkinje cells (PC) appearing more vulnerable
than other cell types (65).
Compared to other tissues/organs, the metabolism of Chol
inside the brain is rather unique. Since Chol does not cross the
BBB, which completely forms after birth (61), brain Chol comes
exclusively from de novo synthesis. During embryonic and early
postnatal neurogenesis Chol synthesis occurs in both neurons
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and glial cells, while subsequently Chol produced by astrocytes
is delivered to neurons via the LDL pathway and made available
to the various cell compartments by NPC1/2-mediated Chol ef-
flux from lysosomes (66,67). This shift is expected to unmask
the neuronal vulnerability to the deficiency of either proteins
and to affect developmental processes. The morphogenesis of
the cerebellar cortex is paradigmatic of such a condition, since
it encompasses the 3 weeks after birth and is marked by intense
neuronal/glial cell proliferation and migration, neurite out-
growth, synaptogenesis and myelin formation, which likely
maximize the need for Chol (68).
Our recent studies in mouse models have shown that Npc1
deficiency affects later steps of cerebellar morphogenesis, in
spite of normal cerebellum development at earlier stages (69).
We found various subtle developmental defects, including the
premature exit from cell cycle of granule neuron (GN) precur-
sors (69) and abnormal differentiation of Bergman glia (BG) (70).
Dysregulated development of both GN and BG is likely to af-
fect the integrity of PC, contributing to their subsequent neuro-
degeneration. In fact, the reduced proliferation of GNs affects
the constant ratio of 175 GN for each PC (71) typical of the nor-
mal mouse cerebellum, whereas the defective scaffolding activ-
ity of BG does not properly support PCs (72).
Defects of cerebellar morphogenesis of Npc1 mice are linked
to altered Shh signaling (11,12,69). This finding is consistent
with the tight relationship between Chol metabolism and Shh
signaling as indicated by the following evidence. First, active
Shh protein is modified by covalent addition of Chol during its
intracellular processing (73). Shh Chol modification is relevant
for generating temporal and spatial gradients of this protein
(74), which likely mediate pleiotropic signaling activities within
the developing cerebellum. Starting from mouse embryonal day
17.5 (E17.5), Shh is continuously secreted by PC and diffuses up-
ward to the external granule layer (EGL) and downward to the
so-called prospective white matter (PWM, a secondary germinal
zone of the postnatal cerebellum), driving the generation of ex-
citatory (GNs) and inhibitory interneurons, respectively. Fate
mapping studies have shown that neural stem cell-like ‘astro-
glial cells’ in the PWM generate these late-born interneurons,
called basket and stellate cells that provide GABAergic input to
the PCs. In response to Shh, a niche of progenitors residing in
the PWM, also generates astrocytes (75).
Second, genes encoding Ptc1 and Npc1 share sequence ho-
mology, mostly confined to their 12 transmembrane segments,
including the sterol-sensing domain, a motif implicated in lipid
intracellular trafficking (52). Accordingly, it was reported that
Ptc1 contributes to Chol efflux from the cell (76). Third, a se-
lected group of compounds inhibits both Shh signaling, regu-
lated by Ptc1, and late endosomal lipid sorting, regulated by
NPC1, suggesting that Ptch1 regulates Smo activity through a
common late endosomal sorting pathway also used by NPC1
protein (77). Fourth, the morphology/function of primary cilium,
a crucial center of Shh signaling transduction, depends on lipid
composition (78). Of note, two studies have recently reported
that the primary cilium length is significantly reduced in NPC
patient fibroblasts and brain sections of Npc1-deficient mice
(11,12).
A recent study further emphasizes the relevance of Chol for
Shh signaling, identifying Smo as the second Chol-modified
protein and showing that the Chol modification of Smo is essen-
tial for Shh signal transduction and proper embryonic develop-
ment (79). The homozygous mutation of the aspartate
aminoacid residues, to which the Chol moiety is bound, is em-
bryonic lethal due to severe cardiac defects.
The phenotype of a mouse model in which a mutation in the
NAD(P)-dependent steroid dehydrogenase-like (Nsdhl) gene
affects the Chol synthesis pathway further strengthens the es-
sential role that Chol has in Shh signaling (80). Similar to Npc1-
deficiency the Nsdhl mutation markedly affects the proliferation
of GN precursors (80).
The requirement of Npc1 function for normal cell move-
ments at the beginning of gastrulation in zebrafish embryos
suggests that this protein might play a relevant role at very
early stages of embryo development. The mouse Npc1 RNA is
able to rescue these zebrafish developmental defects (81), indi-
cating an evolutionarily conserved function.
The role of autophagy and mitophagy in the
neurodegeneration of Niemann-Pick C diseases
There have been multiple studies implicating altered autophagy
in NPC1 but with conflicting results and interpretations. Early
studies suggested enhanced autophagosome activity in the
brain of the NPC1 mouse model with elevated cathepsin D and
LC3-II activity (82). This was confirmed in brain and liver by
Pacheco and Lieberman (83), who found the enhanced autoph-
agy to be associated with increased levels of Beclin-1.
Goldstein’s group knocked down NPC1 function in neurons de-
rived from human embryonic stem cells, finding a strong activa-
tion of autophagy and accumulation of fragmented
mitochondria (84). The autophagic inhibitor, 3-methyladenine
and, also, cyclodextrin reversed the defect (84). The elevated
autophagosome activity was not due to increased formation of
autophagosomes, but rather to a lack of fusion with lysosomes
(85), which seems to be a general defect in LSDs. These authors
emphasized the disagreement in their results and interpreta-
tion of altered autophagy with the results of Pacheco et al. (83)
and Ordonez et al. (84). In particular, they could not reproduce
the finding of elevated levels of Beclin-1. Further studies impli-
cated the lack of SNARE (SNAp [Soluble NSF Attachment
Protein] REceptor) protein recruitment to the endo-lysosome as
the cause of lack of fusion. Importantly, these in vivo studies
confirmed that there was decreased autophagosome activity
due to the lack of fusion with lysosomes in cerebellum and liver
(86). These authors pointed out that an excess of cyclodextrin
could be harmful by preventing the key role of normal autoph-
agy in cellular homeostasis (86). The Lieberman group came to
agreement with these conclusions when they studied the
effects of the tau knockout with Npc1 deficiency (87) and dem-
onstrated impaired proteolysis (88). Autophagic flux involves
microtubules which interact with tau and the lack of tau exacer-
bated the Npc1 phenotype. While studying the defect in auto-
phagosome flux in induced pluriportent stem cells from NPC1
patients, Maetzel et al. (89) found that carbamazine, a known
stimulants of autophagy, decreased Chol storage, especially
when combined with HPbCD.
An alternative mechanism of inhibition of autophagosome-
lysosome fusion was proposed to be due to sphingosine accu-
mulation (90). Evidence was provided for a decreased level of
VEGF a protein well known in lymphatic and blood vasculature
formation, with subsequent depression of sphingosine kinase
activity. A mechanism for this surprising decrease of VEGF was
not given but cross-breeding with a VEGF over-expressing trans-
genic line led to a modest increase in survivial rates of the Npc1
null mice (90). Necroptosis, a form of cell death involving RIP1
and RIP3 kinases has also been implicated in the death of NPC1
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neurons and its inhibition with a RIP1 antagonist extended sur-
vival in Npc1 model mice (91).
A primary initiator of autophagic irregularities in NPC1 may
be the accumulation of altered mitochondria. The mitochon-
drial role in autophagy is well recognized as they supply the
membranes for the formation of the autophagosomes during
starvation (92). As studied in neurons, there is increased mito-
chondrial membrane Chol in NPC1 mutant cells and brains (93).
The route of this Chol to mitochondrial membranes obviously
does not require the missing NPC1 protein but rather the NPC2
(94) and the MNL64 proteins (95). When over-expressed, MLN64
leads to increased mitochondrial membrane Chol with subse-
quent impairment of function and smaller and rounded mito-
chondria (96). The route for Chol movement to the
mitochondrial outer membrane involves the Chol binding pro-
teins StARD1 (the major regulator of Chol biosynthesis) and
StarD3 (97), while the former, along with the translocator pro-
tein, TSPO, is involved in the transport of Chol from the outer to
the inner mitochondrial membrane (98). Importantly, StarD1 ex-
pression is increased in Npc1 deficient mice (99) providing one
possible mechanism for the increased mitochondrial Chol
(reviewed in 100). Mitochondria with increased membrane Chol
show multiple metabolic abnormalities (93,96), including de-
creased membrane potential, decreased ATP synthase activity,
fragmentation and increased ROS. Quite opposite results, with
increased mitochondrial activity, were found by Wos et al. (101)
in cultured primary fibroblasts from patients. ROS have often
been implicated in NPC1 pathology (102) and glutathione, which
reduces ROS, extends life expectancy in the Npc1 model mice
(99). Since caveolin 1 has been shown to have a role in mediat-
ing autophagy and preventing ROS activity (at least in endothe-
lial cells; 103), the elevation of caveolin 1 seen in NPC1 (104)
may be a secondary cellular response to ROS-dependent stress.
Defective mitochondria, with increased levels of oxidative
stress markers and decreased survival (shortened chronological
life span) were also found in the yeast model of NPC1 (105).
These defects seemed to be secondary to elevated sphingolipid
levels.
Alterations in in lysosomal calcium levels due to sphingo-
sine accumulation have been previously shown by Lloyd-Evans
et al. (106). A defect in calcium release was found to be a more
general defect in LSDs, including NPC1, but lysosomal calcium
levels were found to be normal (107). A third group found low
lysosomal calcium levels which could be raised, and Chol stor-
age corrected, by stimulation of the adenosine receptor A2A
(108). Thus, although there is a disagreement about whether
lysosomal calcium is decreased, there is agreement that cal-
cium release is abnormal, whether or not it is due to initially
low levels of calcium.
There are many other proteins involved in mitophagy which
could be altered in NPC1. These include the outer mito mem-
brane receptor Atg32, its partner Atg11, and CK2 kinase need to
phosphorylate it (reviewed in 109). The PINK1-PRKN/PRK2 path-
way, well studied in Parkinson’s disease, senses mito depolari-
zation, which leads to outer mito membrane ubiquitination and
mitophagy (109).
In addition to ‘classical’ mitophagy of defective mitochon-
dria in the autophagosome, there is some evidence for an alter-
native route for removing them involving mitochondria-derived
vesicles. These incorporate oxidized mitochondrial fragments
and are delivered directly to the lysosome (110). Alterations of
this pathway in LSDs has not been explored yet to our knowl-
edge. A further pathway of interest involves the small GTPase
Rab7, which influences endosome motility and is also
implicated in mitochondrial-lysosome contact (111). Its over-
expression corrected the abnormalities of Chol storage in cul-
tured NPC1 cells (112).
It is clear that defective mitophagy allows these abnormal
mitochondria to persist when they should be removed (86) and
the defect may be due to increased Chol in membranes as out-
lined above for MPSs pathogenesis. However, mitochondrial
alterations may themselves cause altered autophagy.
Mitochondria associate with a special portion of the endoplas-
mic reticulum named mitochondria-associated ER membranes
(MAM). This location is the major site of phospholipid, Chol es-
ter, and fatty acid metabolism (113). Experimental evidence has
suggested that MAMs-related abnormalities, especially as indi-
cated by the differences between ApoE4 and ApoE3 effects are
the primary problem in both sporadic late-onset Alzheimers
disease (SLAD) and genetic Alzheimers disease (presenilin and
amyloid precursor protein mutations) (113). NPC1 has been
called ‘juvenile Alzheimers’. The similarity between NPC and
Alzheimer is based on the presence of neurofibrallary tangles,
influence of APOE-4 genotype on severity, and the association
of variants in the human NPC1 gene with the onset of sporadic,
late onset Alzheimers (114,115). Thus, it might be anticipated
that similar alterations in lipid and phospholipid synthesis, af-
fecting phagosome-lysosome fusion and leading to the same
pro-inflammatory events described above in MPSs, may be pre-
sent in NPC1.
Altered mitochondrial respiration may also be important for
impaired autophagy. As studied in T cells, markedly reduced
mitochondrial respiration is associated with decreased
autophagosome-lysosome fusion with subsequently increased
inflammatory responses (116). Thus, altered mitochondria have
multiple roles in autophagy.
Another possibly anomalous relationship of NPC1 to autoph-
agy concerns the target of rapamycin, TOR. The TOR kinase is
the major inhibitory signal of autophagy in the presence of
abundant nutrients. NPC1 is part of a signaling complex that
activates TOR in the presence of Chol (117). While free Chol is
abundant in NPC1 lysosomes, in normal cells, NPC1 binds to a
TOR regulating protein, SLC389, to inhibit TOR. Thus, autophagy
would not be expected to be decreased. Again, in vivo, autoph-
agy is increased but abnormal. These studies have been per-
formed in cultured cells under oxidative stress i.e. at 20%
oxygen instead of the physiological 5% level. Also, it is possible
that the very excessive levels of free Chol present in NPC1 cells
would overcome the absent/decreased TOR signaling due to the
down-regulation of autophagy. Finally, it must be remembered
that autophagy is an ancient process and involves redundancy
with over 100 proteins involved. Combined loss of function of
different autophagic-related proteins is likely to be needed to
evaluate the relation between autophagic defects and NPC
disease.
A somewhat alternative view of the role of mitochondrial
dysfunction in LSDs has been presented by Saffari et al. (39). In
their view, the MAM-related, altered Caþþ flux plays a major
role in mediating the subsequent neurodegeneration. They also
emphasize the release of mitochondrial contents, which can
stimulate apoptosis. However, as mentioned above (MPSII sec-
tion), apoptosis does not stimulate the immune response, while
autophagy does. In addition, it has been previously shown that
the major process of cell death in a Npc1 mouse model does not
involve apoptosis since over-expression of Bcl2, an inhibitor of
apoptosis, did not change the rate of PC death or the progress of
the disease (118).
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The subsequent stimulus to inflammation, primarily medi-
ated by microglia (50) follows the pathway described above for
MPSII with the additional wrinkle that over expression of VEGF,
as mentioned above, seems to have a protective effect (119). The
neuroinflammatory pathway has also been specifically studied
in the olfactory bulb of NPC1 model mice. Seo et al. (120) ex-
plored the mechanism of activation of the neuropathic micro-
glial response in the olfactory system, finding that the cysteine
endopeptidase, Ctss, is involved in the activation of its target,
Cx3cl1 (also known as neurotactin), resulting in p38 mitogen-
activated protein kinase signaling (120). The nasal delivery of
antibody to Cx3cl1 was shown to decrease the number of dam-
aged OB neurons and slightly enhance olfaction (120).
Given the abundant evidence for neuroinflammation, it is
also important to note that drugs primarily directed against in-
flammation, such as vitamin E (121), curcumin (122), and non-
steroidal anti-inflammatory drugs (123), have only had modest
effects in alleviating neurodegeneration. In contrast, the group
studying neuroinflammation in the olfactory bulb found that a
4 weeks treatment with cyclosporine A markedly reduced neu-
roinflammation in the olfactory epithelium (124).
Conclusions
Since the discovery of the pathological hallmarks, clinical mani-
festations of MPSII and NPC1, 2 have been related to the accu-
mulation of GAGs and unesterified Chol, respectively. More
recently this perspective has been enlarged thanks to a number
of studies showing that authophagic flux and signaling path-
ways are altered in both diseases. These anomalies largely pre-
cede the onset of symptoms and are likely to also affect
developmental trajectories that are essential for proper organ
morphogenesis. The occurrence of developmental defects in af-
fected patients should be further considered to secure a more
exhaustive comprehension of the diseases. The finding that the
genetic defect of either MPSII or NPC1, 2 leads to an impairment
of the Shh signaling is particularly significant since it provides
the basis for a ‘convergent hypothesis’ to partly explain the
pathogenesis of these diseases. In addition, it might be also rel-
evant for finding novel therapeutic avenues.
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